Home → E-shop → Nucleotides → Clofarabine diphosphate – CAS 167620-89-5

Clofarabine diphosphate – CAS 167620-89-5

Clofarabine diphosphate – CAS 167620-89-5 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Clofarabine diphosphate Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg		€ 700	Stock
Do you want custom amount?				Custom amount

Amount

1 mg

€ 700

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 167620-89-5

IUPAC name: ((2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methyl trihydrogen diphosphate

Other names: Clofarabine-5′-diphosphate;

Molecular weight: 463.64 g/mol

Molecular formula: C₁₀H₁₃ClFN₅O₉P₂

InChI: InChI=1S/C10H13ClFN5O9P2/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(18)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-4,6,9,18H,1H2,(H,22,23)(H2,13,15,16)(H2,19,20,21)/t3-,4+,6-,9-/m1/s1

Description

Clofarabine diphosphate is metabolite of Clofarabine, a nucleoside analog, used to treat cancers such as leukemia, lymphoma, and solid tumors. Clofarabine has been demonstrated to cause low harm in healthy cells and is generally well tolerated by patients. It inhibits DNA synthesis in rapidly dividing cells. This effect can work in conjunction with other anti-cancer drugs, such as the cytotoxic agent Bleomycin. Clofarabine binds to an intracellular target, preventing DNA synthesis by inhibiting the enzyme DNA polymerase. Inhibition of this enzyme causes cell death. Clofarabine has been studied on pediatric patients ranging in age from one month to 18 years. The medicine has been determined to be safe for use in this demographic.

Chemicals are distributed worldwide

Buy Clofarabine diphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Gandhi, V., Kantarjian, H., Faderl, S., Bonate, P., Du, M., Ayres, M., … & Plunkett, W. (2003). Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical cancer research, 9(17), 6335-6342.
Zhenchuk, A., Lotfi, K., Juliusson, G., & Albertioni, F. (2009). Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochemical pharmacology, 78(11), 1351-1359.